659 related articles for article (PubMed ID: 24837511)
1. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
[TBL] [Abstract][Full Text] [Related]
2. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
3. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
4. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
5. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.
Schijns V; Tartour E; Michalek J; Stathopoulos A; Dobrovolskienė NT; Strioga MM
Cytotherapy; 2014 Apr; 16(4):427-39. PubMed ID: 24280238
[TBL] [Abstract][Full Text] [Related]
6. Fas-deficient fully allogeneic dendritic cells administered via an intratumoral injection route show efficient antitumor effects in murine models.
Okano S; Kondoh H; Toshima T; Nakagawara H; Yoshizumi T; Soejima Y; Shirabe K; Harada M; Yoshikai Y; Maehara Y
Fukuoka Igaku Zasshi; 2013 Jan; 104(1):15-26. PubMed ID: 23600321
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic cancer vaccines.
Acres B; Paul S; Haegel-Kronenberger H; Calmels B; Squiban P
Curr Opin Mol Ther; 2004 Feb; 6(1):40-7. PubMed ID: 15011780
[TBL] [Abstract][Full Text] [Related]
8. The use of dendritic cells in cancer immunotherapy.
Nencioni A; Grünebach F; Schmidt SM; Müller MR; Boy D; Patrone F; Ballestrero A; Brossart P
Crit Rev Oncol Hematol; 2008 Mar; 65(3):191-9. PubMed ID: 18055210
[TBL] [Abstract][Full Text] [Related]
9. Multiple-purpose immunotherapy for cancer.
Seledtsov VI; Goncharov AG; Seledtsova GV
Biomed Pharmacother; 2015 Dec; 76():24-9. PubMed ID: 26653546
[TBL] [Abstract][Full Text] [Related]
10. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell vaccines for cancer immunotherapy.
Timmerman JM; Levy R
Annu Rev Med; 1999; 50():507-29. PubMed ID: 10073291
[TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy: new insights].
Geissler M; Weth R
Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040
[TBL] [Abstract][Full Text] [Related]
13. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory.
Schirrmacher V
Cancer Immunol Immunother; 2005 Jun; 54(6):587-98. PubMed ID: 15838708
[TBL] [Abstract][Full Text] [Related]
15. mRNA-based dendritic cell vaccines.
Benteyn D; Heirman C; Bonehill A; Thielemans K; Breckpot K
Expert Rev Vaccines; 2015 Feb; 14(2):161-76. PubMed ID: 25196947
[TBL] [Abstract][Full Text] [Related]
16. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
17. Personalized approaches to active immunotherapy in cancer.
Ophir E; Bobisse S; Coukos G; Harari A; Kandalaft LE
Biochim Biophys Acta; 2016 Jan; 1865(1):72-82. PubMed ID: 26241169
[TBL] [Abstract][Full Text] [Related]
18. Cancer therapy and vaccination.
Aly HA
J Immunol Methods; 2012 Aug; 382(1-2):1-23. PubMed ID: 22658969
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-based vaccines: clinical applications in breast cancer.
Gelao L; Criscitiello C; Esposito A; De Laurentiis M; Fumagalli L; Locatelli MA; Minchella I; Santangelo M; De Placido S; Goldhirsch A; Curigliano G
Immunotherapy; 2014; 6(3):349-60. PubMed ID: 24762078
[TBL] [Abstract][Full Text] [Related]
20. Considerations on clinical use of T cell immunotherapy for cancer.
Plautz GE; Cohen PA; Shu S
Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]